Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01788774 is registered in ClinicalTrials.gov with Rovi Pharmaceuticals Laboratories as lead sponsor.

NCT NCT01788774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01788774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Rovi Pharmaceuticals Laboratories
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
February 28, 2014
Enrollment
36 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia